原发性硬化性胆管炎：年度随访时碱性磷酸酶升高的患者。 - Suppr

Suppr

超能文献

Primary sclerosing cholangitis: patients with a rising alkaline phosphatase at annual follow-up.

作者信息

Charatcharoenwitthaya Phunchai, Lindor Keith D

机构信息

Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.

出版信息

Clin Gastroenterol Hepatol. 2007 Jan;5(1):32-6. doi: 10.1016/j.cgh.2006.10.021.

DOI:10.1016/j.cgh.2006.10.021

PMID:17234554

Abstract

摘要

相似文献

Primary sclerosing cholangitis: patients with a rising alkaline phosphatase at annual follow-up.

Clin Gastroenterol Hepatol. 2007 Jan;5(1):32-6. doi: 10.1016/j.cgh.2006.10.021.

The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid.

Eur J Gastroenterol Hepatol. 2007 Jun;19(6):487-91. doi: 10.1097/MEG.0b013e3281108068.

The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.

Am J Gastroenterol. 2000 Jan;95(1):204-7. doi: 10.1111/j.1572-0241.2000.01685.x.

Screening and diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis.

Rev Gastroenterol Disord. 2009 Spring;9(2):E41-7.

The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.

Aliment Pharmacol Ther. 2005 Nov 1;22(9):783-8. doi: 10.1111/j.1365-2036.2005.02650.x.

Cholangiocarcionoma and primary sclerosing cholangitis: the answer lies within.

Gastrointest Endosc. 2014 May;79(5):780-2. doi: 10.1016/j.gie.2013.12.022.

Recent insights in primary sclerosing cholangitis.

J Dig Dis. 2012 Jul;13(7):337-41. doi: 10.1111/j.1751-2980.2012.00605.x.

Is a raised CA 19-9 level diagnostic for a cholangiocarcinoma in patients with no history of sclerosing cholangitis ?

Dig Surg. 2006;23(5-6):319-24. doi: 10.1159/000098014. Epub 2006 Dec 14.

Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis.

J Gastrointest Surg. 1999 Jul-Aug;3(4):357-67; discussion 367-8. doi: 10.1016/s1091-255x(99)80051-1.

Early detection and treatment of cholangiocarcinoma.

Liver Transpl. 2000 Nov;6(6 Suppl 2):S30-4. doi: 10.1053/jlts.2000.18688.

引用本文的文献

Hepatobiliary and pancreatic manifestations in inflammatory bowel disease: an umbrella review of meta-analyses.

Therap Adv Gastroenterol. 2025 Jan 6;18:17562848241311165. doi: 10.1177/17562848241311165. eCollection 2025.

Noninvasive prognostic models, imaging, and elastography to predict clinical events in primary sclerosing cholangitis: A review.

World J Hepatol. 2023 Sep 27;15(9):1013-1020. doi: 10.4254/wjh.v15.i9.1013.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Primary sclerosing cholangitis: patients with a rising alkaline phosphatase at annual follow-up.

作者信息

Charatcharoenwitthaya Phunchai, Lindor Keith D

机构信息

Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.

出版信息

Clin Gastroenterol Hepatol. 2007 Jan;5(1):32-6. doi: 10.1016/j.cgh.2006.10.021.

DOI:10.1016/j.cgh.2006.10.021

PMID:17234554

Abstract

摘要

相似文献

Primary sclerosing cholangitis: patients with a rising alkaline phosphatase at annual follow-up.

Clin Gastroenterol Hepatol. 2007 Jan;5(1):32-6. doi: 10.1016/j.cgh.2006.10.021.

The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid.

Eur J Gastroenterol Hepatol. 2007 Jun;19(6):487-91. doi: 10.1097/MEG.0b013e3281108068.

The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.

Am J Gastroenterol. 2000 Jan;95(1):204-7. doi: 10.1111/j.1572-0241.2000.01685.x.

Screening and diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis.

Rev Gastroenterol Disord. 2009 Spring;9(2):E41-7.

The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.

Aliment Pharmacol Ther. 2005 Nov 1;22(9):783-8. doi: 10.1111/j.1365-2036.2005.02650.x.

Cholangiocarcionoma and primary sclerosing cholangitis: the answer lies within.

Gastrointest Endosc. 2014 May;79(5):780-2. doi: 10.1016/j.gie.2013.12.022.

Recent insights in primary sclerosing cholangitis.

J Dig Dis. 2012 Jul;13(7):337-41. doi: 10.1111/j.1751-2980.2012.00605.x.

Is a raised CA 19-9 level diagnostic for a cholangiocarcinoma in patients with no history of sclerosing cholangitis ?

Dig Surg. 2006;23(5-6):319-24. doi: 10.1159/000098014. Epub 2006 Dec 14.

Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis.

J Gastrointest Surg. 1999 Jul-Aug;3(4):357-67; discussion 367-8. doi: 10.1016/s1091-255x(99)80051-1.

Early detection and treatment of cholangiocarcinoma.

Liver Transpl. 2000 Nov;6(6 Suppl 2):S30-4. doi: 10.1053/jlts.2000.18688.

引用本文的文献

Hepatobiliary and pancreatic manifestations in inflammatory bowel disease: an umbrella review of meta-analyses.

Therap Adv Gastroenterol. 2025 Jan 6;18:17562848241311165. doi: 10.1177/17562848241311165. eCollection 2025.

Noninvasive prognostic models, imaging, and elastography to predict clinical events in primary sclerosing cholangitis: A review.

World J Hepatol. 2023 Sep 27;15(9):1013-1020. doi: 10.4254/wjh.v15.i9.1013.